NCT03849456View on ClinicalTrials.gov

Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

May 26, 2020

Study Completion Date

May 26, 2020

Conditions
Autism Spectrum Disorder
Interventions
DRUG

GWP42006

Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.

Trial Locations (3)

40202

Clinical Trial Site, Louisville

43205

Clinical Trial Site, Columbus

02421

Clinical Trial Site, Lexington

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY